The US health regulator has a closed warning letter issued for three sites of Dr. Reddy's Laboratories in Andhra Pradesh and Telangana, following evaluation of corrective actions taken by the company.
In November 2015, it had received a warning letter from the US Food and Drug Administration (USFDA) for three of its sites -- active pharmaceutical ingredient (API) manufacturing facilities at Srikakulam, Andhra Pradesh, and Miryalguda, Telangana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
